Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Codexis Inc | CDXS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.65 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.45 - 4.91 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 2.65 | USD |
Codexis Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
186.3M | 70.30M | - | 70.14M | -76.24M | -1.08 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Codexis News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CDXS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.77 | 3.03 | 2.64 | 2.80 | 271,538 | -0.12 | -4.33% |
1 Month | 3.49 | 3.535 | 2.57 | 2.99 | 344,058 | -0.84 | -24.07% |
3 Months | 2.68 | 4.91 | 2.53 | 3.48 | 578,555 | -0.03 | -1.12% |
6 Months | 1.64 | 4.91 | 1.51 | 2.88 | 676,412 | 1.01 | 61.59% |
1 Year | 4.07 | 4.91 | 1.45 | 2.63 | 840,894 | -1.42 | -34.89% |
3 Years | 24.30 | 42.01 | 1.45 | 10.35 | 773,635 | -21.65 | -89.09% |
5 Years | 19.27 | 42.01 | 1.45 | 12.11 | 629,086 | -16.62 | -86.25% |
Codexis Description
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. |